224 related articles for article (PubMed ID: 38096229)
1. Deciphering the immune landscape of head and neck squamous cell carcinoma: A single-cell transcriptomic analysis of regulatory T cell responses to PD-1 blockade therapy.
Miraki Feriz A; Bahraini F; Khosrojerdi A; Azarkar S; Sajjadi SM; HosseiniGol E; Honardoost MA; Saghafi S; Silvestris N; Leone P; Safarpour H; Racanelli V
PLoS One; 2023; 18(12):e0295863. PubMed ID: 38096229
[TBL] [Abstract][Full Text] [Related]
2. Tumor microenvironmental modification by the current target therapy for head and neck squamous cell carcinoma.
Okuyama K; Naruse T; Yanamoto S
J Exp Clin Cancer Res; 2023 May; 42(1):114. PubMed ID: 37143088
[TBL] [Abstract][Full Text] [Related]
3. Immune Checkpoint Expression on Immune Cells of HNSCC Patients and Modulation by Chemo- and Immunotherapy.
Puntigam LK; Jeske SS; Götz M; Greiner J; Laban S; Theodoraki MN; Doescher J; Weissinger SE; Brunner C; Hoffmann TK; Schuler PJ
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32707816
[TBL] [Abstract][Full Text] [Related]
4. B-cell infiltration is associated with survival outcomes following programmed cell death protein 1 inhibition in head and neck squamous cell carcinoma.
Gavrielatou N; Fortis E; Spathis A; Anastasiou M; Economopoulou P; Foukas GRP; Lelegiannis IM; Rusakiewicz S; Vathiotis I; Aung TN; Tissot S; Kastrinou A; Kotsantis I; Vagia EM; Panayiotides I; Rimm DL; Coukos G; Homicsko K; Foukas P; Psyrri A
Ann Oncol; 2024 Apr; 35(4):340-350. PubMed ID: 38159908
[TBL] [Abstract][Full Text] [Related]
5. Novel Effector Phenotype of Tim-3
Liu Z; McMichael EL; Shayan G; Li J; Chen K; Srivastava R; Kane LP; Lu B; Ferris RL
Clin Cancer Res; 2018 Sep; 24(18):4529-4538. PubMed ID: 29712685
[No Abstract] [Full Text] [Related]
6. Blockade of TIGIT/CD155 Signaling Reverses T-cell Exhaustion and Enhances Antitumor Capability in Head and Neck Squamous Cell Carcinoma.
Wu L; Mao L; Liu JF; Chen L; Yu GT; Yang LL; Wu H; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Cancer Immunol Res; 2019 Oct; 7(10):1700-1713. PubMed ID: 31387897
[TBL] [Abstract][Full Text] [Related]
7. Molecular phenotypes of circulating tumor cells and efficacy of nivolumab treatment in patients with head and neck squamous cell carcinoma.
Tada H; Takahashi H; Kawabata-Iwakawa R; Nagata Y; Uchida M; Shino M; Ida S; Mito I; Matsuyama T; Chikamatsu K
Sci Rep; 2020 Dec; 10(1):21573. PubMed ID: 33299117
[TBL] [Abstract][Full Text] [Related]
8. Complement C3a and C5a receptor blockade modulates regulatory T cell conversion in head and neck cancer.
Gadwa J; Bickett TE; Darragh LB; Knitz MW; Bhatia S; Piper M; Van Court B; Bhuvane S; Nguyen D; Nangia V; Kleczko EK; Nemenoff RA; Karam SD
J Immunother Cancer; 2021 Mar; 9(3):. PubMed ID: 33789881
[TBL] [Abstract][Full Text] [Related]
9. Dynamic profiling of immune microenvironment during anti-PD-1 immunotherapy for head and neck squamous cell carcinoma: the IPRICE study.
Hélène C; Conrad O; Pflumio C; Borel C; Voegelin M; Bernard A; Schultz P; Onea MA; Jung A; Martin S; Burgy M
BMC Cancer; 2023 Dec; 23(1):1209. PubMed ID: 38066522
[TBL] [Abstract][Full Text] [Related]
10. Squamous Cell Carcinomas of the Head and Neck Cancer Response to Programmed Cell Death Protein-1 Targeting and Differential Expression of Immunological Markers: A Case Report.
Merhi M; Raza A; Inchakalody VP; Nashwan AJJ; Allahverdi N; Krishnankutty R; Uddin S; Zar Gul AR; Al Homsi MU; Dermime S
Front Immunol; 2018; 9():1769. PubMed ID: 30108590
[TBL] [Abstract][Full Text] [Related]
11. Multi-Omics Data Analyses Identify B7-H3 as a Novel Prognostic Biomarker and Predict Response to Immune Checkpoint Blockade in Head and Neck Squamous Cell Carcinoma.
Lin W; Xu Y; Gao J; Zhang H; Sun Y; Qiu X; Huang Q; Kong L; Lu JJ
Front Immunol; 2021; 12():757047. PubMed ID: 34675936
[TBL] [Abstract][Full Text] [Related]
12. HGF-Induced PD-L1 Expression in Head and Neck Cancer: Preclinical and Clinical Findings.
Boschert V; Teusch J; Aljasem A; Schmucker P; Klenk N; Straub A; Bittrich M; Seher A; Linz C; Müller-Richter UDA; Hartmann S
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233528
[TBL] [Abstract][Full Text] [Related]
13. Blockade of adenosine A2A receptor enhances CD8
Ma SR; Deng WW; Liu JF; Mao L; Yu GT; Bu LL; Kulkarni AB; Zhang WF; Sun ZJ
Mol Cancer; 2017 Jun; 16(1):99. PubMed ID: 28592285
[TBL] [Abstract][Full Text] [Related]
14. MYC-PDL1 axis reduces sensitivity to nivolumab in recurrent head and neck squamous cell carcinoma.
Noji R; Kano Y; Hirai H; Onishi I; Nishii N; Yoshimura R; Miyake S; Ikeda S; Harada H
Oral Oncol; 2022 Jan; 124():105666. PubMed ID: 34896892
[TBL] [Abstract][Full Text] [Related]
15. The Evolving Landscape of PD-1/PD-L1 Pathway in Head and Neck Cancer.
Qiao XW; Jiang J; Pang X; Huang MC; Tang YJ; Liang XH; Tang YL
Front Immunol; 2020; 11():1721. PubMed ID: 33072064
[TBL] [Abstract][Full Text] [Related]
16. Differential contribution of three immune checkpoint (VISTA, CTLA-4, PD-1) pathways to antitumor responses against squamous cell carcinoma.
Kondo Y; Ohno T; Nishii N; Harada K; Yagita H; Azuma M
Oral Oncol; 2016 Jun; 57():54-60. PubMed ID: 27208845
[TBL] [Abstract][Full Text] [Related]
17. Immune gene expression in head and neck squamous cell carcinoma patients.
Lecerf C; Kamal M; Vacher S; Chemlali W; Schnitzler A; Morel C; Dubot C; Jeannot E; Meseure D; Klijanienko J; Mariani O; Borcoman E; Calugaru V; Badois N; Chilles A; Lesnik M; Krhili S; Choussy O; Hoffmann C; Piaggio E; Bieche I; Le Tourneau C
Eur J Cancer; 2019 Nov; 121():210-223. PubMed ID: 31593831
[TBL] [Abstract][Full Text] [Related]
18. Upregulation of secreted phosphoprotein 1 affects malignant progression, prognosis, and resistance to cetuximab via the KRAS/MEK pathway in head and neck cancer.
Liu K; Hu H; Jiang H; Liu C; Zhang H; Gong S; Wei D; Yu Z
Mol Carcinog; 2020 Oct; 59(10):1147-1158. PubMed ID: 32805066
[TBL] [Abstract][Full Text] [Related]
19. Association of a gene-expression subtype to outcome and treatment response in patients with recurrent/metastatic head and neck squamous cell carcinoma treated with nivolumab.
Serafini MS; Cavalieri S; Licitra L; Pistore F; Lenoci D; Canevari S; Airoldi M; Cossu Rocca M; Strojan P; Kuhar CG; Merlano M; Perrone F; Vingiani A; Denaro N; Perri F; Argiris A; Gurizzan C; Ghi MG; Cassano A; Allegrini G; Bossi P; De Cecco L
J Immunother Cancer; 2024 Jan; 12(1):. PubMed ID: 38290766
[TBL] [Abstract][Full Text] [Related]
20. Immunotherapy of head and neck squamous cell carcinoma (HNSCC). Immune checkpoint blockade.
Przybylski K; Majchrzak E; Weselik L; Golusiński W
Otolaryngol Pol; 2018 Sep; 72(6):10-16. PubMed ID: 30647199
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
